[Immunotherapy for HIV infections].
HIV infection leads to a severe decrease of T CD4 lymphocytes with subsequent development of opportunistic infections. The use of current combination of antivirals has improved the morbidity and morbility of patients. Such treatments are not without severe drawbacks such as toxicity and resistance. Development of additional therapeutic strategies with cytokines, immunomodulators or therapeutic immunizations are currently intensely investigated. The clinical benefit of such strategies is under evaluation. However, these strategies may help to potentiate the immune restoration obtained with antivirals or alternatively to spare or delay the use of antivirals.
Service d'immunologie clinique, Hôpital Henri Mondor 51, avenue du Maréchal de Lattre de Tassigny, 94010 Créteil.
Pr Yves
PY
Lévy
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D016207:Cytokines